EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)

Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation

Sara Lonardi iD, Cosimo Rasola iD, Riccardo Lobefaro iD, Daniele Rossini, Vincenzo Formica iD, Mario Scartozzi, Giovanni Luca Frassineti, Giorgia Boscolo, Saverio Cinieri, Samantha Di Donato, Nicoletta Pella, Francesca Bergamo iD und 16 weitere

Journal of Clinical Oncology · 2023

DOI: 10.1200/jco.23.00506 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2023. Verfasst von Sara Lonardi und 27 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To verify whether both doublet chemotherapy with a modified schedule of fluorouracil, leucovorin, and oxaliplatin (mFOLFOX) and monochemotherapy with fluorouracil plus leucovorin (5-FU + LV) achieve satisfactory efficacy when both regimens are combined with panitumumab (PAN) as initial treatment of elderly patients with RAS/ BRAF wild-type metastatic colorectal cancer (mCRC). PATIENTS AND METHODS PANDA (ClinicalTrials.gov identifier: NCT02904031 ) was an open-label, randomized phase II noncomparative trial in previously untreated patients age 70 years and older with unresectable RAS/ BRAF wild-type mCRC. Patients were randomly assigned 1:1 to mFOLFOX + PAN (arm A) or 5-FU + LV + PAN (arm B) for up to 12 cycles, followed by PAN maintenance. The primary end point was progression-free survival (PFS). In each arm, assuming a null hypothesis of median PFS time ≤6 months and target PFS ≥9.65, 90 patients per arm were needed to achieve 90% power and 5% type I error (one-sided Brookmeyer-Crowley test). RESULTS Between July 2016 and April 2019, 91 patients were randomly assigned to arm A and 92 to arm B. At a median follow-up of 50.0 months (IQR, 45.6-56.4), median PFS was 9.6 and 9.0 months for arm A and B, respectively ( P < .001 in each arm). Overall response rate was 69% and 52%, whereas median overall survival was 23.5 and 22.0 months in arm A and B, respectively. The overall rate of grade >2 chemotherapy-related adverse events was 60% and 37%, respectively. Baseline G8 and Chemotherapy Risk Assessment Scale for High-Age Patients scores were prognostic, but they were not associated with efficacy and safety of the two arms. CONCLUSION Both mFOLFOX and 5-FU + LV + PAN are reasonable options as initial therapy of elderly patients with RAS/ BRAF wild-type mCRC. 5-FU + LV + PAN is associated with a better safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsColonic NeoplasmsRectal NeoplasmsHumansAgedPanitumumabOxaliplatinProto-Oncogene Proteins B-rafLeucovorinFluorouracilAntineoplastic Combined Chemotherapy Protocols

Substanzen

PanitumumabOxaliplatinProto-Oncogene Proteins B-rafLeucovorinFluorouracilBRAF protein, human

Autor:innen und Institutionen

  • Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
  • Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Unit of Medical Oncology 2, University Hospital of Pisa, Pisa, Italy.
  • Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Medical Oncology Unit, Policlinico Tor Vergata, Roma, Italy.
  • Department of Medical Sciences and Public Health, Medical Oncology Unit, "Azienda Ospedaliero Universitaria" of Cagliari, University of Cagliari, Cagliari, Italy.

ORCID-Profile: Sara Lonardi, Cosimo Rasola, Riccardo Lobefaro, Vincenzo Formica, Francesca Bergamo, Federica Morano, Matteo Fassan, Chiara Cremolini, Luca Boni, Filippo Pietrantonio

Zitieren

APA

Lonardi, S., Rasola, C., Lobefaro, R., Rossini, D., Formica, V., Scartozzi, M., Frassineti, G. L., Boscolo, G., Cinieri, S., Di Donato, S., Pella, N., Bergamo, F., Raimondi, A., Arnoldi, E., Antonuzzo, L., Granetto, C., Zustovich, F., Ronzoni, M., Leo, S., …, & GONO Foundation Investigators (2023). Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.00506

Vancouver

Lonardi S, Rasola C, Lobefaro R, Rossini D, Formica V, Scartozzi M, et al. Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation. Journal of Clinical Oncology. 2023. doi:10.1200/jco.23.00506

BibTeX
@article{Lonardi2023,
  author = {Lonardi, Sara and Rasola, Cosimo and Lobefaro, Riccardo and Rossini, Daniele and Formica, Vincenzo and Scartozzi, Mario and Frassineti, Giovanni Luca and Boscolo, Giorgia and Cinieri, Saverio and Di Donato, Samantha and Pella, Nicoletta and Bergamo, Francesca and Raimondi, Alessandra and Arnoldi, Ermenegildo and Antonuzzo, Lorenzo and Granetto, Cristina and Zustovich, Fable and Ronzoni, Monica and Leo, Silvana and Morano, Federica and Loupakis, Fotios and Buggin, Federica and Zagonel, Vittorina and Fassan, Matteo and Cremolini, Chiara and Boni, Luca and Pietrantonio, Filippo and GONO Foundation Investigators, GONO Foundation Investigators},
  title = {Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  doi = {10.1200/jco.23.00506}
}
Kostenlos starten →